The Gemelli University Hospital is a large general hospital in Rome, Italy. With 1575 beds, it is the second-largest hospital in Italy, the largest hospital in Rome and one of the largest private hospitals in Europe.

There are 1,575 beds in Divisione di Ematologia - Istituto di Semeiotica Medica - Policlinico A. Gemelli.

During the past decade, Divisione di Ematologia - Istituto di Semeiotica Medica - Policlinico A. Gemelli conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 4 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Divisione di Ematologia - Istituto di Semeiotica Medica - Policlinico A. Gemelli" #1 collaborator was "Azienda Policlinico Umberto I" with 2 trials as a collaborator, "Associazione Italiana di Immunogenetica e Biologia dei Trapianti (AIBT)" with 1 trials as a collaborator, "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia" with 1 trials as a collaborator, "National Marrow Donor Program" with 1 trials as a collaborator and "University of Rome Tor Vergata" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Divisione di Ematologia - Istituto di Semeiotica Medica - Policlinico A. Gemelli" are "Hematologic Diseases" (4 trials), "Stem Cell Transplant Complications" (3 trials), "Myelofibrosis" (2 trials), "Acute Myeloblastic Leukemia" (1 trials) and "Acute Myeloid Leukemia (AML)" (1 trials). Many other conditions were trialed in "Divisione di Ematologia - Istituto di Semeiotica Medica - Policlinico A. Gemelli" in a lesser frequency.

Most popular intervention types in "Divisione di Ematologia - Istituto di Semeiotica Medica - Policlinico A. Gemelli" are "Drug" (9 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Alentuzumab" (1 trials), "Azacitidine" (1 trials), "BIVV009" (1 trials), "Busulphan plus Cyclophosphamide" (1 trials) and "Busulphan plus Fludarabine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Divisione di Ematologia - Istituto di Semeiotica Medica - Policlinico A. Gemelli" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Divisione di Ematologia - Istituto di Semeiotica Medica - Policlinico A. Gemelli". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Divisione di Ematologia - Istituto di Semeiotica Medica - Policlinico A. Gemelli, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Divisione di Ematologia - Istituto di Semeiotica Medica - Policlinico A. Gemelli, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".